ArticleRevista brasileira de hematologia e hemoterapia
Results of high-risk neutropenia therapy of hematology-oncology patients in a university hospital in Uruguay.
Article in Revista brasileira de hematologia e hemoterapia. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 15 citations in OpenAlex.
- Parallel Toxicities: A Comparative Analysis of Chemotherapy-Induced Neutropenia and Alopecia.Cancers · 2025Review
- Does age play a role in fever and neutropenia events and complications: A comparison of adolescents versus younger children with cancer at a tertiary care pediatric hospital, a pilot project.Cancer reports (Hoboken, N.J.) · 2023Review
- Impact of cardiovascular comorbidities on inpatient mortality in patients hospitalized with neutropenic fever.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021Article
- Outcomes of hospitalized hematologic oncology patients receiving rapid response system activation for acute deterioration.Critical care (London, England) · 2019Article
- Bacterial Spectrum and Antimicrobial Resistance Pattern in Cancer Patients with Febrile NeutropeniaAsian Pacific journal of cancer prevention : APJCP · 2019Article
- Chemotherapy-induced neutropenia among pediatric cancer patients in Egypt: Risks and consequences.Molecular and clinical oncology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFebrile neutropenia is an important cause of mortality and morbidity in hematology-oncology patients undergoing chemotherapy. The management of febrile neutropenia is typically algorithm-driven. The aim of this study was to assess the results of a standardized protocol for the treatment of febrile neutropenia.
methodsA retrospective cohort study (2011-2012) was conducted of patients with high-risk neutropenia in a hematology-oncology service.
resultsForty-four episodes of 17 patients with a median age of 48 years (range: 18-78 years) were included. The incidence of febrile neutropenia was 61.4%. The presence of febrile neutropenia was associated with both the duration and severity of neutropenia. Microbiological agents were isolated from different sources in 59.3% of the episodes with bacteremia isolated from blood being the most prevalent (81.3%). Multiple drug-resistant gram-negative bacilli were isolated in 62.5% of all microbiologically documented infections. Treatment of 63% of the episodes in which the initial treatment was piperacillin/tazobactam needed to be escalated to meropenem. The mortality rate due to febrile neutropenia episodes was 18.5%.
conclusionThe high rate of gram-negative bacilli resistant to piperacillin/tazobactam (front-line antibiotics in our protocol) and the early need to escalate to carbapenems raises the question as to whether it is necessary to change the current protocol.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.